Senzime 25 years!

• Expanded US commercial operations
• Received largest US deal ever
• New sustainable headquarter office in Uppsala, Sweden
• First Group Purchasding Organziation contract with major US hospital system
• Expanded reach in Japan through integrated TetraGraph module by Fukuda Denshi
• Granted new European TetraGraph system patent
• Secured contract with highest ranked children's hospital in the US
• New studies out confirming TetraGraph's leading accuracy and precision

• Commercial breakthrough year with sales growth of 155%
• Growth driven by new clinical guidelines from leading anesthesia societies in US and Europe
• Secured multiple university hospital order in Germany
• Expanded partnership with Fukuda Denshi
• Outlicenced ExSpiron in Chinese market
• First step launched in partnership with Masimo
• Received ISO 14001 certification for headquarters in Sweden
• Launch of TetraSensitive, first EMG sensor for sensitive skin
• Several new studies validating the TetraGraph technology
• Senzime's share cross-traded at US-based OTCQX list

• FDA 510k-clearance for new disposable sensor intended for monitoring of children

• Acquisition of Respiratory Motion

• Strategic license and connectivity agreement with Masimo

• CE-MDR approval for new disposable sensor intended for small children

• US and European guidelines for neuromuscular blockade management

• Inauguration of Senzime’s manufacturing facility in Uppsala, Sweden

• Senzimes TetraGraph system and new manufacturing facility certified against MDR

• Listed on Nasdaq Stockholm’s main market

• Establishing a subsidiary in Germany, receives first breakthrough order from German university hospital

• Establishing a subsidiary in the US, Senzime Inc

• Building a sales organisation and receiving breakthrough order from a US university hospital

• Marketing approval for TetraGraph in the US, Japan and South Korea

• Senzime listed on Nasdaq Stockholm First North Growth Market

• Licensing agreement with Fukuda Denshi in Japan.

• Acquired Acacia Designs B.V. and obtained TetraGraph, broadening the product range to include solutions for patients undergoing anesthesia.

• Senzime acquires MD Biomedical AB, the developer of OnZurf Probe, a new generation of microdialysis catheters.

Patent obtained for CliniSenz, a blood glucose analyzer for post-operative and continuous monitoring of patients in a hospital environment.

• Senzime is admitted to trading on Aktietorget.

The first prototype is completed: CliniSenz – a blood glucose analyzer for post-operative and continuous monitoring of patients in a hospital environment.

• The Crafoord family, represented by Adam Dahlberg a long-term member of the Board of Directors of Senzime AB, invested in the company.

• Senzime is founded with the business idea of developing patient-oriented systems for measuring life-critical substances.